TABLE 3.
Medications after HTX – stratified by T2DM at HTX.
| Parameter | All (n = 376) | T2DM (n = 121) | No T2DM (n = 255) | Difference | 95% CI | P-value |
| Immunosuppressive drug therapy | ||||||
| Cyclosporine A, n (%) | 124 (33.0%) | 36 (29.8%) | 88 (34.5%) | 4.7% | –5.3 – 14.7% | 0.359 |
| Tacrolimus, n (%) | 252 (67.0%) | 85 (70.2%) | 167 (65.5%) | 4.7% | –5.3 – 14.7% | 0.359 |
| Azathioprine, n (%) | 46 (12.2%) | 16 (13.2%) | 30 (11.8%) | 1.4% | –5.8 – 8.6% | 0.687 |
| Mycophenolate mofetil, n (%) | 330 (87.8%) | 105 (86.8%) | 225 (88.2%) | 1.4% | –5.8 – 8.6% | 0.687 |
| Steroids, n (%) | 376 (100.0%) | 121 (100.0%) | 255 (100.0%) | 0.0% | n. a. | n. a. |
| Concomitant medications | ||||||
| ASA, n (%) | 47 (12.5%) | 14 (11.6%) | 33 (12.9%) | 1.3% | –5.8 – 8.4% | 0.707 |
| Beta blocker, n (%) | 85 (22.6%) | 25 (20.7%) | 60 (23.5%) | 2.8% | –6.1 – 11.7% | 0.534 |
| Ivabradine, n (%) | 44 (11.7%) | 14 (11.6%) | 30 (11.8%) | 0.2% | –6.7 – 7.1% | 0.956 |
| Calcium channel blocker, n (%) | 110 (29.3%) | 42 (34.7%) | 68 (26.7%) | 8.0% | –2.1 – 18.1% | 0.109 |
| ACE inhibitor/ARB, n (%) | 159 (42.3%) | 52 (43.0%) | 107 (42.0%) | 1.0% | –9.7 – 11.7% | 0.852 |
| Diuretic, n (%) | 376 (100.0%) | 121 (100.0%) | 255 (100.0%) | 0.0% | n. a. | n. a. |
| Statin, n (%) | 211 (56.1%) | 73 (60.3%) | 138 (54.1%) | 6.2% | –4.5 – 16.9% | 0.257 |
| Gastric protection †, n (%) | 376 (100.0%) | 121 (100.0%) | 255 (100.0%) | 0.0% | n. a. | n. a. |
ACE inhibitor, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; CI, confidence interval; HTX, heart transplantation; n, number; n. a., not applicable; T2DM, type 2 diabetes mellitus; †, gastric protection defined as proton pump inhibitor (PPI) or histamine receptor (H2) blocker.